Fintel reports that on December 20, 2024, Chardan Capital initiated coverage of Mind Medicine (NasdaqGS:MNMD) with a Buy recommendation.
Analyst Price Forecast Suggests 287.13% Upside
As of December 3, 2024, the average one-year price target for Mind Medicine is $27.16/share. The forecasts range from a low of $16.16 to a high of $57.75. The average price target represents an increase of 287.13% from its latest reported closing price of $7.02 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Mind Medicine is 0MM. The projected annual non-GAAP EPS is -3.18.
What is the Fund Sentiment?
There are 262 funds or institutions reporting positions in Mind Medicine. This is an increase of 67 owner(s) or 34.36% in the last quarter. Average portfolio weight of all funds dedicated to MNMD is 0.12%, an increase of 26.04%. Total shares owned by institutions increased in the last three months by 28.88% to 54,125K shares. 
The put/call ratio of MNMD is 0.18, indicating a bullish outlook.
What are Other Shareholders Doing?
Commodore Capital holds 8,000K shares representing 10.91% ownership of the company. In its prior filing, the firm reported owning 7,146K shares , representing an increase of 10.68%. The firm decreased its portfolio allocation in MNMD by 19.12% over the last quarter.
Deep Track Capital holds 7,065K shares representing 9.63% ownership of the company. In its prior filing, the firm reported owning 6,104K shares , representing an increase of 13.61%. The firm decreased its portfolio allocation in MNMD by 2.92% over the last quarter.
Blackstone Group holds 3,912K shares representing 5.34% ownership of the company. In its prior filing, the firm reported owning 1,898K shares , representing an increase of 51.48%. The firm increased its portfolio allocation in MNMD by 32.88% over the last quarter.
Driehaus Capital Management holds 3,894K shares representing 5.31% ownership of the company. In its prior filing, the firm reported owning 2,538K shares , representing an increase of 34.81%. The firm increased its portfolio allocation in MNMD by 7.44% over the last quarter.
Octagon Capital Advisors holds 3,018K shares representing 4.12% ownership of the company. In its prior filing, the firm reported owning 2,153K shares , representing an increase of 28.66%. The firm increased its portfolio allocation in MNMD by 9.48% over the last quarter.
Mind Medicine Background Information
(This description is provided by the company.)
Mind Medicine Inc., also known as MindMed, is a New York-based psychedelic medicine biotech company that develops psychedelic-inspired medicines known as psychoplastogens and therapies to address addiction and mental illness.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
